Subtype
Glioma
CI-CAN-00000935Explore in graph →
Non-malignant787 active trials5 approved drugs147 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000935Explore in graph →
Clinical trials
2,804 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00272870 | Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy | terminated | Phase 1 | 1 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Aug 29, 2012 | clinicaltrials |
| NCT01044225 | Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma | terminated | Phase 2 | 12 | Bart NeynsOTHER |
| 1 |
| Mar 22, 2012 |
| clinicaltrials |
| NCT00389090 | A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma | terminated | Phase 2 | 32 | Keryx / AOI Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 9, 2012 | clinicaltrials |
| NCT00508456 | Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM | terminated | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 16, 2012 | clinicaltrials |
| NCT01105988 | Evaluating Tumor Pseudoprogression With FLT-PET and MRI | terminated | Early Phase 1 | 2 | Massachusetts General HospitalOTHER | 1 | Jan 6, 2012 | clinicaltrials |
| NCT00790452 | Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 8, 2011 | clinicaltrials |
| NCT00515086 | Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 2 | 41 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 22, 2011 | clinicaltrials |
| NCT00062504 | Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas | terminated | Phase 2 | 30 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 0 | May 23, 2011 | clinicaltrials |
| NCT00290771 | Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 2 | 231 | NovartisINDUSTRY | 1 | May 16, 2011 | clinicaltrials |
| NCT00615186 | Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy(Glass-Art) | terminated | Phase 3 | 9 | Bradmer Pharmaceuticals Inc.INDUSTRY | 0 | Feb 10, 2011 | clinicaltrials |
| NCT00826930 | Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma | terminated | Phase 1 | 1 | Diffusion Pharmaceuticals IncINDUSTRY | 1 | Aug 12, 2010 | clinicaltrials |
| NCT00730262 | Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme | terminated | Phase 2 | 40 | Thallion PharmaceuticalsINDUSTRY | 2 | Dec 30, 2009 | clinicaltrials |
| NCT00376103 | Radiation Boost for Newly Diagnosed Glioblastoma Multiforme | terminated | Phase 1 / Phase 2 | 3 | Methodist Healthcare - MemphisOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00548938 | Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM | terminated | Phase 2 | 40 | Methodist Healthcare - MemphisOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00365222 | Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | terminated | Phase 2 | 1 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 22, 2009 | clinicaltrials |
| NCT00115453 | Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma | terminated | Phase 1 / Phase 2 | 50 | Boneca CorporationINDUSTRY | 1 | Aug 18, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Aug 29, 2012source: clinicaltrials